Hitoshi Masuda

Hitoshi Masuda

Auto-generated profile, based on publicly available information

Hitoshi Masuda


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2003 in Journal of Urology
Verified
Journal Article
Closed access
HMHitoshi Masuda
Hitoshi Masuda
MUMasayasu Urushibara
Masayasu Urushibara
KKKazunori Kihara
Kazunori Kihara

1 November 2002 in Journal of Urology
Verified
Journal Article
Closed access
HMHitoshi Masuda
Hitoshi Masuda
TOTetsuo Okuno
Tetsuo Okuno
MSMasahito Suzuki
Masahito Suzuki
KKKazunori Kihara
Kazunori Kihara
MGMoritaka Goto
Moritaka Goto
HAHiroshi Azuma
Hiroshi Azuma
Conclusions In the detrusor NOS and soluble guanylate cyclase activities were mainly detected in the mucosa, while in the urethra these activities were distributed throughout the mucosa and muscularis. Also, the mucosa in the urethra but not in the detrusor contributed to electrical field stimulation induced, NO mediated relaxation. These findings confirm previous studies demonstrating that NO has a different role in the detrusor than in the proximal urethra.

7 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SYShugo Yajima
Shugo Yajima
HMHitoshi Masuda
Hitoshi Masuda
Background/Objectives: Urothelial carcinoma (UC) treatment has been transformed by immunotherapy and antibody-drug conjugates (ADCs). This review evaluates the current evidence for these approaches and identifies future directions. Methods: We conducted a structured review of clinical trials, meta-analyses, and guidelines published until early 2025. Results: Immune checkpoint inhibitors have established benefits across multiple settings: post-platinum therapy (pembrolizumab, nivolumab), maintenance therapy (avelumab), adjuvant settings for high-risk muscle-invasive disease (nivolumab), and BCG-unresponsive non-muscle-invasive disease (pembrolizumab). Enfortumab vedotin (targeting Nectin-4) has proven effective in post-platinum/post-immunotherapy. Most significantly, enfortumab vedotin plus pembrolizumab has redefined first-line treatment with unprecedented survival benefits (median OS 31.5 months vs. 16.1 months with chemotherapy; HR 0.47), and nivolumab plus gemcitabine-cisplatin improved outcomes in cisplatin-eligible patients. Key challenges include managing unique toxicity profiles, optimizing treatment sequencing, and developing reliable biomarkers. Conclusions: Combination approaches offer the most promising path forward, with future research needed on resistance mechanisms, biomarker development, and expanding these therapies to earlier disease stages.

1 February 1998 in Journal of Urology
Verified
Journal Article
Closed access
TMTakashi Morita
Takashi Morita
HMHitoshi Masuda
Hitoshi Masuda
ATAkira Tosaka
Akira Tosaka
KIKazuhiro Ishizaka
Kazuhiro Ishizaka
TTToshihiko Tsujii
Toshihiko Tsujii
SKShun Kondo
Shun Kondo
To examine whether there are sex-related differences in urinary bladder function, we evaluated the function and distribution of beta-adrenoceptor in the male and female rabbit urinary bladder. Ten male and ten female rabbits were studied. The function and distribution of beta-adrenoceptors were studied by measuring changes in contractile forces from isoproterenol, a beta-adrenoceptor agonist, and forskolin, an adenylate cyclase activator, and by measuring beta-adrenoceptor densities using radioligand receptor binding techniques. Isoproterenol caused significantly greater relaxation in female trigonal muscles than in male trigonal muscles. It caused similar relaxation responses in the male and female detrusors. The Bmax values for [3H]dihydroalprenolol (DHA) binding in trigonal muscles were significantly higher in the female than in the male, whereas Bmax values for [3H]DHA binding in the male and the female detrusor were similar. In contrast, forskolin caused similarly marked relaxations in the male and the female detrusor and trigonal muscles. These findings demonstrate that there are sex-related differences in the function and the distribution of beta-adrenoceptors in rabbit trigonal smooth muscles.

1 April 1999 in International Journal of Urology
Verified
Journal Article
Open access
PDF file
CAChizuru Arisawa
Chizuru Arisawa
KKKazunori Kihara
Kazunori Kihara
Yasuhisa FujiiYasuhisa Fujii
Yasuhisa Fujii
KIKazuhiro Ishizaka
Kazuhiro Ishizaka
HMHitoshi Masuda
Hitoshi Masuda
HOHiroyuki Oshima
Hiroyuki Oshima
Purpose: We report on two cases of retroperitoneal lymph node metastasis of testicular cancer with left inferior vena cava.Methods/Results: A 25‐year‐old man with a left testicular cancer with pulmonary and retroperitoneal lymph node metastases received three courses of VIP (etoposide, ifosfamide and cisplatinum) chemotherapy. Subsequent abdominal computed tomography (CT) revealed round lesions enhanced with contrast agent on both sides of the aorta inside the degenerated lymphadenopathy. These lesions were regarded as a duplicated inferior vena cava (IVC) and this was confirmed at retroperitoneal lymph node dissection. The second case is of a 21‐year‐old man with a left testicular cancer with pulmonary, liver and widespread lymph node metastases. Subsequent to a course of VIP chemotherapy, super high‐dose chemotherapy was administered. Abdominal CT revealed a round mass enhanced with contrast agent on the left side of the aorta adjacent to the degenerated lymphadenopathy, which was regarded as the transposed left IVC and this was confirmed at lymph node dissection.Conclusions: In both cases, initial CT failed to detect the lesions as the left IVC and there was a possibility for the misinterpretation of such venous anomalies with residual lymphadenopathy.

1 January 2004 in Journal of Urology
Verified
Journal Article
Closed access
TYTomoko Yamashita
Tomoko Yamashita
HMHitoshi Masuda
Hitoshi Masuda
MYMasataka Yano
Masataka Yano
TKTsuyoshi Kobayashi
Tsuyoshi Kobayashi
KKKeizo Kawano
Keizo Kawano
KKKazunori Kihara
Kazunori Kihara